Description  of  Spnib 50mg (Dasatinib 50mg)

Spnib 50mg (Dasatinib 50mg) belongs to oral dual BCR/ABL and Src group of tyrosine kinase inhibitor approved for use in patients with chronic myelogenous leukaemia (CML). The main aim of Sprycel, are BCRABL, SRC, Ephrin’s and GFR.
Spnib 50mg (Dasatinib 50mg) is a prescription drug which used under the supervision of doctor.

INDICATIONS of  Spnib 50mg (Dasatinib 50mg)

Spnib 50mg (Dasatinib 50mg) is indicated for the treatment of adult patients having chronic myeloid leukaemia.
Spnib 50mg (Dasatinib 50mg) is indicated for the treatment of adult patients having acute lymphoblastic leukaemia